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1. Introduction  
Several studies have focused on the identification of patients at risk of sudden cardiac death, 
which is mostly due to depolarization and repolarization impairment. The measurement of 
QT interval indicates the total duration of ventricular myocardial depolarization and 
repolarization. Localized repolarization data can be obtained easily from the standard 12-
lead electrocardiogram (ECG), a non-invasive method extensively used as a tool for 
cardiovascular risk assessment. [1,2] Non-uniform myocardial repolarization time may 
result from inhomogeneity, variation of action potential duration between the individual 
leads of the 12-lead ECG, or localized delay in activation due to slow conduction or altered 
conduction pathways. To ensure the recording of the earliest depolarization at the latest 
repolarization of the ventricular myocardium, the maximum QT interval should be 
measured from the beginning of the earliest QRS complex to the end of the latest T wave 
from all leads of a simultaneous 12-lead ECG. Nevertheless, the QT interval may reflect 
increased inhomogeneity of myocardial repolarization, resulting from delayed 
repolarization in some areas of the myocardium, and it can be caused by a uniform increase 
in action potential duration. A measure that can help differentiate between these two 
conditions is the QT dispersion. Using both the QT prolongation and the QT dispersion the 
individual lead variation and the interlead variation provide a measure of repolarization 
heterogeneity. [3] 
The QT interval prolongation has been proposed as a marker of cardiovascular risk in the 
clinical setting and it has also been particularly associated with arrhythmias, sudden death 
and poor survival in apparently healthy subjects. [4,5] As for diabetic subjects, although 
some cross-sectional studies suggest that glycemic control, ischemic heart disease, and blood 
pressure, among other risk factors, are associated with the QT interval prolongation, its 
pathogenesis remains unclear. [6,8] Also, and increased mortality in newly diagnosed type 2 
diabetes patients has been associated with QT interval prolongation. [9,10] 
The aim of this study was to estimate the prevalence of QTc interval prolongation in diabetic 
and non-diabetic subjects, as well as to evaluate cross-sectionally and prospectively the 
associated risk factors of QTc interval prolongation and its clinical implications in subjects 
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with and without type 2 diabetes who had not suffered from previous myocardial infarction 
corroborated on the ECG.  
2. Methods 
The Mexico City Diabetes Study is a prospective, population-based investigation designed 
to describe the prevalence and incidence of diabetes and cardiovascular risk factors in low-
income urban population from Mexico City. The detailed methodology has been reported 
elsewhere. [11] Briefly, the sample size included 2282 men and non-pregnant women aged 
35 to 64 years who completed a baseline interview and physical examination in 1989-1990. 
Two follow-up visits were carried out in 1994-1996 (n=1773) and in 1998-2000 (n=1764). All 
evaluations included medical history, physical examination, ECG, and several laboratory 
tests. Current smoking was defined as at least one cigarette per day in the last year. Physical 
examination included an anthropometric evaluation with participants wearing lightweight 
clothing and no shoes. Height was measured using a stadiometer with subjects standing on 
the floor with the back against a wall; weight was measured using a clinical scale. Body 
mass index (BMI) was calculated as weight/height2 in kg/m2. Waist circumference (WC) 
was measured considering the umbilicus as the landmark. Systolic (SBP) and diastolic blood 
pressure (DBP) were measured 3 times in the right arm of seated subjects (after resting for at 
least 5 min) using a random zero sphygmomanometer (Hawksley, London). We used the 
average of the last 2 readings as the BP of the participants. Hypertension was defined as 
SBP140 mmHg, DBP90 mmHg, or treatment with antihypertensive drugs. In every visit, 
participants completed a 75-g oral glucose tolerance test. Diabetes was defined according to 
the World Health Organization criteria with a fasting glucose ≥7mmol/l (126 mg/dl), 2-
hour glucose ≥11.1 mmol/l (200 mg/dl), or treatment with oral antidiabetic drugs. [12] 
Fasting and 2-hour plasma glucose and insulin as well as fasting serum lipids and all other 
biomarkers were measured using previously reported methods [13] at the research 
laboratory of the Division of Clinical Epidemiology at the Medicine Department of the 
University of Texas Health Science Center at San Antonio, USA. Insulin resistance was 
estimated by the homeostasis model (HOMA-IR) as follows: [fasting insulin (units/ml) X 
fasting glucose (mmol/l)/22.5].  
A resting standard 12-lead ECG was taken with the subject in a supine position at each 
examination. A standard interpretation of ECGs at a reading center (Wake Forest 
University, EPICARE Center) was made using the Minnesota Code. [14] Heart rate (HR), 
QRS duration, R amplitude in AVL lead (R-AVL), S amplitude in V3 lead (SV3), left 
ventricular hypertrophy (LVH), QT interval, and myocardial infarction, among other 
variables, were coded. Left ventricular hypertrophy (LVH) was defined as (R-AVL) + (SV3) 
≥2600μv in men and ≥2200μv in women. Myocardial infaction was defined according to the 
following codes: Q-QS pattern with 1.1-1.2.7, Q-QS and T wave pattern 1.2.8-1.3, and wave T 
pattern with 5.1-5.3. QT interval was measured from the electrocardiogram tracing in lead II 
and defined as the first deflection of the QRS complex and the end as the point of maximal 
change in the slope as the T wave merges with the baseline. QT corrected (QTc) was 
calculated according to Bazzett’s formula as QT/square root of (R–R interval). The same 
measurement instruments were used throughout the study.  
The Institutional Review Boards of both The University of Texas Health Science Center and 
the Centro de Estudios en Diabetes approved the study protocol. Each participant gave 
informed consent. For this analysis, we included 1661 subjects, 218 with and 1443 without 
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type 2 diabetes, without myocardial infarction at baseline corroborrated by ECG, who were 
followed-up for a median of time of 4.26 and 3.32 years, respectively.  
2.1 Statistical analysis 
Comparisons of clinical and laboratory features were made according to diabetes status at 
baseline. Proportions and means (standard deviation [s.d.]) were compared by Pearson Chi2 
and by T student, respectively, while medians (interquartile range [IQR]) were compared by 
Wilcoxon test. QTc interval was analyzed as continuous and dichotomous variable. Because 
of the normal distribution of the QTc interval, all analyses were carried out using the 
original units. QTc interval prolongation, using the Bazzett´s formula, was defined as an 
interval ≥430 msec in men and 450 msec in women. Partial Pearson correlation between QTc 
interval and some risk factors were estimated in diabetic and non-diabetic subjects, 
separately. To estimate the association between some cardiovascular risk factors and QTc 
interval prolongation in diabetic and non-diabetic subjects, both together and separately, 
multiple linear regression for cross-sectional analysis and generalized estimating equations 
regression models (GEE), with family normal identity link, for longitudinal analysis were 
carried out. Models were performed with the forward method considering the biological 
and statistical relevance. Results are given as regression β coefficients and 95% confidence 
interval (95%CI). P value equal or less than 0.05 was considered significant. All analyses 
were done with Stata/SE 9.0 (Stata statistical software: Release 9. College Station. Texas: 
Stata Corporation, 2005). 
3. Results 
Characteristics of the sample 
A total of 1661 subjects (1443 non-diabetic and 218 diabetic subjects), aged 47.4±8.2 years at 
baseline were included. Table 1 shows comparisons of some QT interval risk factors 
between subjects with and without type 2 diabetes. Individuals with diabetes were older 
and had greater abdominal fat and upper-body fat accumulation, as well as higher BP levels, 
total cholesterol and fasting and 2-hour glucose levels compared with individuals without 
diabetes. The percentage of hypertension was higher for subjects with diabetes (27.1%) 
compared with non-diabetic subjects (13.0%); likewise, the proportion of individuals under 
antihypertensive medication was slightly greater in the diabetic group. Although the 
percentage of subjects who were under antihyperlipidemic medication was higher in 
subjects with diabetes compared with non-diabetic subjects, these differences were not 
significant. As for diabetic subjects, 136 (62.4%) were prevalent cases whereas 82 (37.6%) 
were incident cases, with a ratio 1:1.6. Mean of age at diagnosis of diabetes was 46.6 years 
(s.d. 8.0 years) and median of diabetes duration was 1.8 (IQR 25-75% 0-7.3).   
Some characteristic on the ECG were compared between diabetic and non-diabetic subjects 
at baseline and during follow-up and are shown in table 2. The mean of heart rate, QRS 
duration, and R amplitude in AVL lead were significant higher in diabetic compared with 
non-diabetic subjects. Mean of QTc by the Bazzet´s formula was significantly higher 
(p<0.001) in diabetic (414.0 msec) than in non-diabetic (404.3 msec) individuals. The 
prevalence of longer QTc interval (≥430 msec in men and ≥450 msec in women) was greater 
in diabetic (10.1%) compared with non-diabetic subjects (4.0%). Prevalence was remarkably 
higher in both diabetic and non-diabetic men (16.3% vs. 4.5%, p<0.001) compared with 
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Non-diabetic 
subjects 
Diabetic subjects p value 
 n=1443 n=218  
Age (years) 46.6 (8.0) 52.5 (7.7) <0.001 
Age at diabetes diagnosis (years) - 47.8 (8.3) - 
Women (no., %) 848 (58.8) 138 (63.3) 0.204 
Current smoking (no., %) 487 (33.8) 65 (30.0) 0.269 
BMI (kg/m2) 28.0 (4.3) 29.1 (4.8) 0.001 
Waist circumference (cm)    
Men 93.6 (9.1) 98.8 (11.7) <0.001 
Women 97.8 (13.4) 101.6 (11.5) 0.002 
Hypertension (no., %) 188 (13.0) 61 (28.0) <0.001 
SBP (mmHg) 115.6 (16.1) 122.9 (18.6) <0.001 
DBP (mmHg) 72.5 (10.3) 75.4 (9.6) <0.001 
Total cholesterol (mmol/L)* 4.9 (4.2-5.6) 5.2 (4.5-5.9) <0.001 
HDL-C, (mmol/L)*    
Men 0.7 (0.6-0.9) 0.8 (0.7-0.9) 0.319 
Women 0.9 (0.7-1.0) 0.9 (0.7-1.0) 0.334 
Triglycerides (mmol/L)* 1.9 (1.4-2.8) 2.5 (1.8-3.6) <0.001 
Fasting glucose (mmol/L)* 4.7 (4.2-5.1) 8.9 (6.6-13.5) <0.001 
2-hour glucose (mmol/L)* 5.7 (4.6-6.8) 14.1 (11.6-18.8) <0.001 
Antihypertensive medication (no., %)† 67 (35.6) 27 (44.3) 0.227 
Antihyperlipidemic medication (no., %) 4 (0.3) 1 (0.5) 0.638 
Diabetes cases    
Prevalent - 136 (62.4) - 
Incident - 82 (37.6) - 
Hypoglycemic medication (no., %) - 143 (65.9) - 
Diabetes duration (years)* - 1.8 (0-7.3) - 
Duration of follow-up (years)* 3.32 (3.15-3.74) 4.26 (4.00-4.44) 0.0001 
*Median (IQR 25-75). 
†Only subjects with hypertension. 
Missing values in non-diabetic subjects: WC, 26; HDL-C, 2; 2-hour glucose, 1; antihyperlipidemic 
medication, 37.  
Missing values in diabetic subjects: current smoking, 1; WC, 3; triglycerides, 2; 2-hour glucose, 122; 
antihyperlipidemic medication, 9. 
Table 1. Characteristic of the study population by diabetes status 
women (6.5% vs. 3.7%, p>0.05). Similar differences were observed on the QTc interval as 
continuous and dichotomous variable during the follow-up. In addition, after stratifying by 
hypertension, prevalence of longer QTc interval was significantly higher in both diabetic 
(13.3%) and non-diabetic subjects (5.2%) with hypertension compared with diabetic (8.9%) 
and non-diabetic subjects (3.8%) without hypertension. When stratification was made by 
BMI<25 and BMI≥25, prevalence remained significantly higher in diabetic compared with 
non-diabetic subjects with normal weight (14% vs. 1.8%, respectively) and with 
overweigh/obesity (9.1% vs. 4.7%, respectively). 
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Non-diabetic 
subjects 
Diabetic subjects p value 
 
n=1443 
mean (s.d.) 
n=218 
mean (s.d.) 
 
At baseline    
Heart rate (bpm) 65.2 (9.2) 70.9 (12.0) <0.001 
QRS duration (msec) 90.9 (10.4) 88.9 (10.7) 0.007 
R amplitude in AVL lead 294.4 (239.8) 346.8 (270.5) 0.003 
S amplitude in V3 lead 879.9 (523.3) 917.2 (545.1) 0.330 
LVH, no (%) 33 (2.3) 6 (2.8) 0.672 
QT interval (msec) 390.0 (25.4) 384.3 (28.5) 0.002 
QTc interval by the Bazzett´s formula 
(msec)  
404.3 (22.5) 414.5 (23.8) <0.001 
QTc interval by the Bazzett´s formula ≥430 
in men and ≥450 in women (no., %)  58 (4.0) 22 (10.1) <0.001 
At the end of follow-up    
Heart rate (bpm) 62.8 (9.5) 66.6 (9.4) <0.0001 
QRS duration (msec) 89.9 (10.9) 88.0 (15.2) 0.027 
R amplitude in AVL lead 338.5 (224.5) 369.0 (233.4) 0.063 
S amplitude in V3 lead 815 (434.7) 880.3 (503.5) 0.045 
LVH, no (%) 20 (1.4) 6 (2.8) 0.130 
QTc interval by the Bazzett´s formula 
(msec)  
406.7 (22.3) 416.1 (21.6) <0.001 
QTc interval by the Bazzett´s formula ≥430 
in men and ≥450 in women (no., %)      77 (5.3) 20 (9.2) 0.024 
Missing values in non-diabetic subjects: S amplitude in V3 lead 1. 
Bazzett´s formula: QT/square root of (R–R interval). 
Table 2. QTc interval segment and other electrocardiographic parameters in subjects with 
and without type 2 diabetes  
Figure 1 shows the relation between QTc interval and BMI in subjects with and without type 
2 diabetes according to age. The values of QTc interval were slightly greater in subjects with 
greater BMI in both diabetic and non-diabetic individuals, regardless of age group. A 
similar trend was observed when BMI was substituted for WC. (Data not shown) 
As for fasting glucose in diabetic subjects, a slight increment in the QTc interval was 
observed in subjects with higher levels of fasting glucose, particularly in subjects with levels 
between 12 mmol/l and 20 mmol/l. (Figure 2) For non-diabetic subjects, a modest 
increment in the QTc interval was observed when 2-hour glucose (≥6 mmol/l) and HOMA-
IR (≥10 units) increased (Figure 3).       
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Fig. 1. Comparison between QTc interval level and BMI at baseline in subjects with and without 
type 2 diabetes stratifying by age <50 (upper panel) years and ≥50 years (bottom panel). 
In diabetic subjects, partial Pearson correlations with QTc interval were statistically 
significant for age (rho=0.15, p=0.024), BMI (rho=0.19, p=0.006), and WC (rho=0.20, 
p=0.003). No significant correlation with diabetes duration was observed. In non-diabetic 
subjects, correlations with QTc interval were significant for age (rho=0.16, p<0.0001), SPB 
(rho=0.10, p=0.0002), DBP (rho=0.07, p=0.008), BMI (rho=0.23, p<0.0001), and WC (rho=0.21, 
p<0.0001). During follow-up, the correlation of QTc interval with BMI and WC remained 
significant (p<0.001) in both diabetic (BMI, rho=0.24 and WC, rho=0.25) and non-diabetic 
individuals (BMI, rho =0.23 and WC, rho=0.26). 
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Fig. 2. Comparison between QTc interval level and fasting glucose level at baseline in 
subjects with type 2 diabetes. 
Cross-sectional analysis 
In the whole sample, QTc interval prolongation was significantly associated with age, sex, 
BMI, and diabetes. For each unit of change on age (year), the QTc interval increased 0.36 
msec (95%CI 0.23; 0.49). For each unit of increment on BMI, the QTc interval increased 0.75 
msec (95%CI 0.51; 1.00). Women had a greater QTc interval mean than men (difference of 
13.36 msec (95%CI 11.36; 15.76). Regarding diabetes, the difference on the QTc interval 
between diabetic and non-diabetic subjects was 6.33 msec (95%CI 3.24; 9.43). Models 
stratified by diabetes status were also performed. In diabetic subjects, risk factors 
significantly associated with QTc interval were sex and BMI, whereas age had a borderline 
significance. For each unit of increment on BMI, the QTc interval increased 0.72 msec (95%CI 
0.07; 1.37). Women had a greater QTc interval than men (difference of 15.93 msec, 95%CI 
9.50; 22.35). In non-diabetic subjects, risk factors significantly associated with QTc interval 
were age (beta=0.35, 95%CI 0.21; 0.50), sex (beta=13.69, 95%CI 11.27; 16.10), BMI (beta=0.62, 
95%CI 0.33; 0.91), hypertension (beta=4.18, 95%CI 0.14; 8.22), and HOMA-IR (beta=0.43, 
95%CI 0.08; 0.78) (Table 3). 
Longitudinal analysis  
When the whole sample was considered, the progression of QTc interval prolongation was 
significantly associated with age, sex, BMI, hypertension, and diabetes. The QTc interval 
prolongation increased with age (beta= 0.33, 95%CI 0.24; 0.42) and BMI (beta= 0.73, 95%CI 
0.56; 0.90). Women had a greater QTc interval prolongation than men (difference of 11.84 
msec, 95%CI 10.09; 13.59), as did diabetic compared with non-diabetic subjects (difference of 
6.58 msec, 95%CI 4.02; 9.13). In a model restricted to diabetic subjects, the QTc interval was 
predicted by sex (beta= 11.18, 95%CI 6.27; 16.10), BMI (beta= 0.84, 95%CI 0.38; 1.30), and 
fasting glucose (beta= 0.42, 95%CI 0.11; 0.74). In non-diabetic subjects, predictors of QTc 
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Fig. 3. Comparison between QTc interval level and fasting glucose, 2-hour glucose and 
HOMA-IR levels at baseline in subjects without type 2 diabetes. 
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Non-diabetic subjects
N=1368 
Diabetic subjects 
N=218 
Whole sample 
N=1661 
 
Beta  
(95%CI) 
p 
Beta  
(95%CI) 
p 
Beta  
(95%CI) 
p 
Age (years) 
0.35 
(0.21;0.50) 
<0.001 
0.37 
(-0.04;0.79) 
0.077 
0.36 
(0.23;0.49) 
<0.0001 
Women 
13.69 
(11.27;16.10)
<0.001 
15.93 
(9.50;22.35)
<0.001 
13.56 
(11.36;15.76) 
<0.0001 
BMI (kg/m2) 
0.62 
(0.33;0.91) 
<0.001 
0.72 
(0.07;1.37) 
0.030 
0.75 
(0.51;1.00) 
<0.0001 
Hypertension 
4.18 
(0.14;8.22) 
0.043 
0.93 
 (-6.02;7.88)
0.792 
3.11 
(-0.47;6.69) 
0.088 
HDL-C (mmol/L) 
-2.50 
(-7.68;2.68) 
0.344 
-5.56 
 (-18.67;7.54)
0.404 
-2.69 
(-7.33;1.94) 
0.255 
Fasting glucose 
(mmol/L) 
- - 
0.44 
 (-0.25;1.13)
0.209   
HOMA-IR 
0.43 
(0.08;0.78) 
0.016 - - - - 
Diabetes - - - - 
6.33 
(3.24-9.43) 
<0.0001 
Diabetes duration 
(years) 
- - 
0.28 
(-0.29;0.85) 
0.331 - - 
Antihypertensive 
medication 
-2.26 
(-8.68;4.17) 
0.491 - - 
-1.21 
(-6.64;4.23) 
0.664 
Hypoglycemic 
medication 
- - 
-4.45 
(-11.91;3.00)
0.240 - - 
Table 3. Risk factors associated with the QT interval prolongation in subjects with and 
without type 2 diabetes. Cross-sectional analysis 
interval prolongation were age (beta=0.34, 95%CI 0.25; 0.44), sex (beta=12.23, 95%CI 10.29; 
14.18), BMI (beta=0.64, 95%CI 0.44; 0.83), hypertension (beta=3.72, 95%CI 1.57; 5.87), 
HOMA-IR (beta=0.45, 95%CI 0.16; 0.75) (Table 4). Antihypertensive therapy had a negative 
effect in QTc prolongation. In a multivariate model with diabetes duration equal or greater 
than 1 year, the increment of QT interval prolongation remained similar for fasting glucose 
(beta=0.38, 95%CI 0.06; 0.70, p=0.021), whereas a significant increment with diabetes 
duration was observed (beta=0.42, 95%CI 0.04; 0.80, p=0.032). (Data not shown)  
4. Discussion 
The methods used in the Mexico City Diabetes Study meet the accepted international 
criteria in terms of study protocol,  diagnostic algorithms, and particularly 
electrocardiographic interpretations. [11] The ECGs were interpreted without disclosure of 
clinical or laboratory data, in a reference center recognized as a gold standard for this 
procedure. A rigorous quality control procedure was followed along the study. In this 
population, there is a high prevalence of cardiovascular risk factors, namely overweight, 
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Non-diabetic subjects 
N=1368 
Diabetic subjects 
N=216 
Whole sample 
N=1661 
 
Beta  
(95%CI) 
p 
Beta  
(95%CI) 
p 
Beta  
(95%CI) 
p 
Age  
(years) 
0.34  
(0.25; 0.44) 
<0.0001 
0.22  
(-0.8; 0.53) 
0.151 
0.33  
(0.24; 0.42) 
<0.0001 
Women 
12.23  
(10.29; 14.18)
<0.0001 
11.18  
(6.27; 16.10)
<0.0001
11.84  
(10.09; 13.59) 
<0.0001 
BMI  
(kg/m2) 
0.64  
(0.44; 0.83) 
0.0001 
0.84  
(0.38; 1.30) 
<0.0001
0.73  
(0.56; 0.90) 
<0.0001 
Hypertension 
3.72  
(1.57; 5.87) 
0.001 
1.67  
(-1.80; 5.14)
0.345 
2.63  
(0.74; 4.52) 
0.006 
Fasting glucose  
(mmol/L) 
- - 
0.42 
(0.11; 0.74) 
0.009 - - 
HOMA-IR 
0.45  
(0.16; 0.75) 
0.002 - - - - 
Diabetes - - - - 
6.58  
(4.02; 9.13) 
<0.0001 
Diabetes duration 
(years) 
- - 
0.24  
(-0.12; 0.61)
0.191 - - 
Antihypertensive 
medication 
-3.57  
(-6.50; -0.64)
0.017 - - 
-1.27  
(-3.78; 1.24) 
 
Hypoglycemic 
medication 
- - 
-3.00  
(-8.41; 2.41)
0.277 - - 
Models were run by using generalized estimating equations with family normal and identity link. 
Table 4. Risk factors associated with the QT interval prolongation in subjects with and 
without type 2 diabetes. Longitudinal analysis 
obesity, diabetes, hypertension, and dyslipidemia. [15-17] This circumstance offers a unique 
opportunity to study the effect of the above-mentioned factors on the QTc interval as a 
proxy for the repercussions of the electrophysiologic phenomena on the heart cycle. Our 
findings clearly show the deleterious effects of the identified cardiovascular risk factors on 
the QTc interval, particularly those related to insulin resistance.  
In the present study, prevalence of QTc interval prolongation was higher in diabetic that in 
non-diabetic subjects without previous myocardial infarction detected by ECG, 
independently of age and sex. As expected, subjects with diabetes had 6 times the risk of 
developing QTc interval prolongation compared with non-diabetic subjects. In multivariate 
models, QTc interval prolongation was consistently predicted by sex, BMI, and fasting 
glucose in diabetic subjects. In non-diabetic subjects, age, sex, BMI, hypertension, HOMA-
IR, and antihypertensive medication predicted QTc interval prolongation. In both groups, 
results were largely unchanged when WC was used in place of BMI, or when 2-hour glucose 
was included instead of fasting and HOMA-IR in diabetic and non-diabetic subjects, 
respectively. 
Several studies have demonstrated that the prevalence of prolonged QTc interval is higher 
in subjects with type 2 diabetes (26%) than in subjects without. [18-21] Also, the QTc interval 
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prolongation has been associated with a high risk of ischemic heart disease, ventricular 
fibrillation, and sudden death (range 2 to 5) in several studies, even in subjects with short 
duration of diabetes. [10] In our study, we observed a significantly higher proportion of 
prolonged QTc interval in diabetic compared with non-diabetic subjects (10.1% vs. 4.0%). 
After adjustment for other risk factors, the mean difference on the QTc interval between 
diabetic and non-diabetic subjects was 6.33 msec. It has been suggested that this difference 
relates to the sympathetic activity present in diabetes, which reduces both the ability to 
regulate heart rate and the heart rate variability. [19,20]  
As for diabetes duration, it has been reported as a risk factor for chronic complications, 
including QTc interval prolongation, the latter being related to neuropathy in subjects with 
diabetes. [19] In our study, neither at baseline nor at follow-up duration of diabetes was 
significantly associated with QTc interval, which could be explained, in part, by the high 
proportion of new cases at baseline (37.6%). When the analysis was restricted to subjects 
with diabetes duration equal or greater than 1 year, QTc interval prolongation was 
predicted by duration, independently of other risk factors, despite the short median 
duration of the disease in subjects with previous diagnosis of diabetes (median 5.4 years, 
IQR 2.1-10.6). 
We found a significant prospective association between fasting plasma glucose and 
prolonged QTc interval in diabetic subjects, even after adjustment for other risk factors. 
Some studies have reported an association between fasting glucose and QTc interval, 
particularly in individuals in the normal high level or with impaired fasting glucose, after 
adjustment for diabetes duration, among other risk factors. [21-22] However, other studies 
have not found any significant association. [23] As for non-diabetic subjects, we noted an 
independent association between HOMA-IR and QT-interval prolongation. These results 
showed an important degree of insulin resistance, maybe related to overweight and obesity 
in this population, and both predicted QTc interval prolongation. No association was 
observed with fasting plasma glucose in this group. By contrast, previous studies have 
reported an association between plasma glucose and QT interval in healthy subjects [24], 
even after hyperglycemic clamp insulin release, which suggests that the effect of glucose on 
the QTc interval is not mediated by insulin.  
The association of higher BMI with the prolongation of the QTc interval observed in the 
non-diabetic group is not clearly seen in the diabetic group, probably because of the effect of 
weight loss as a result of poor metabolic control. It is particularly interesting the finding that 
HOMA-IR index has a significant association with the prolongation of the QTc duration in 
both the cross-sectional and the prospective analyses. The pathophysiologic implications 
direct our attention to the cellular effects of insulin resistance in the electrophysiology that 
mediates the depolarization and repolarization of the myocardium. Somewhat surprisingly, 
we could not show a demonstrable effect of therapy for diabetes or hypertension in the QTc 
duration. 
Some of the limitations with the QT interval evaluation relate to the lack of accuracy and 
reproducibility of the measurements, since there is no standard method for analysis and 
lead selection. The definition for the end of the QT interval is unclear as well, and may 
represent a changing T wave morphology that could provide a measure of altered disparity 
of repolarization. [25,26] Nevertheless, its application as a non-invasive and cost-effective 
screening tool is invaluable for cardiovascular risk stratification of population. On the other 
hand, because of the lack of QT interval dispersion measurement in this study, we were not 
able to determine the type of variation on repolarization.  
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5. Conclusion 
In this study, in addition to specific cardiovascular risk factors associated with the QTc 
interval prolongation in diabetic and non-diabetic subjects, general excess of body weight 
measured by BMI was a significant risk factor for both groups. Our findings clearly show 
the deleterious effects of the identified cardiovascular risk factors on the QTc interval, 
particularly those related to insulin resistance. In diabetic subjects, the lack of metabolic 
control (measured by fasting glucose level) predicted strongly the QTc prolongation, 
whereas in non-diabetic subjects the presence of insulin resistance (HOMA-IR) predicted it. 
Given the cardiovascular clinical implications of QTc interval in subjects with and without 
diabetes, further interventional researches are needed to confirm whether the metabolic 
control in diabetic subjects and the decrease of insulin resistance in non-diabetic subjects 
together with weight reduction can prevent QTc interval prolongation.  
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